期刊文献+

ST段抬高型心肌梗死患者PCI术后应用替格瑞洛的临床价值 被引量:5

Clinical Value of in Patients with ST Segment Elevation Myocardial Infarction after PCI
下载PDF
导出
摘要 目的探讨ST段抬高型心肌梗死患者PCI术后应用替格瑞洛治疗的临床价值。方法选取2015年8月至2016年6月在我院接受PCI手术治疗的ST段抬高型心肌梗死患者90例,采用随机数表法将患者分为观察组和对照组,每组患者各45例,观察组患者术后给予替格瑞洛治疗,对照组患者术后给予氯吡格雷治疗,观察比较两组患者治疗后心功能、CI以及SVI改善情况,同时比较两组患者治疗后MACE事件发生率。结果治疗后,两组患者的心功能LVEF都有所升高,观察组(58.12±10.23%)高于对照组(52.12±9.27%),两组比较差异具有统计学意义(P<0.05);治疗后,两组患者的心功能LVDs以及LVDd指标都有所下降,观察组(40.12±5.68 mm、42.23±6.90 mm)低于对照组(48.12±6.90 mm、50.08±8.89 mm),两组比较差异显著(P<0.05);治疗后,两组患者的CI以及SVI指标都有所下降,观察组(2.78±0.57 L.min^(-1).m^(-2)、37.12±8.56 SV(ml/m^2))低于对照组(3.98±1.02 L.min^(-1).m^(-2)、45.12±9.27 SV(ml/m^2))(P<0.05);两组患者治疗后MACE事件总发生率进行比较,差异具有统计学意义(P<0.05)。结论采用替格瑞洛对经PCI治疗的ST段抬高型心肌梗死患者进行治疗,能够有效改善患者的心功能,降低MACE事件发生。
出处 《血栓与止血学》 2018年第1期62-64,共3页 Chinese Journal of Thrombosis and Hemostasis
  • 相关文献

参考文献7

二级参考文献75

  • 1葛均波,徐永健.内科学[M].第8版.北京:人民卫生出版社,2014:385-390.
  • 2Steg PG, James SK, Atar D,et al.ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation [ J ].Eur Heart J,2012, 33(20) : 2569 -2619.
  • 3Wallentin L, Becker RC, Budaj A, et al.Ticagrelor versus clopi-dogrel in patients with acute coronary syndromes [ J ].N Engl J Med, 2009,361(11) : 1045 -1057.
  • 4Kushner FG,Hand M,Smith SC Jr,et al.2009 focused updates :ACC/AHA guidelines for the management of patients with ST-ele-vation myocardial infarction ( updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[ J].Circulation, 2009,120(22) : 2271 -2306.
  • 5O' Gara PT, Kushner FG, Ascheim DD, et al.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].Circulation, 2013,127(4) : e362 -425.
  • 6Levine GN, Bates ER, Blankenship JG, et al.2011 ACCF/ AHA/SCAI guideline for percutaneous coronary intervention.A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions[ J].J Am Coll Caixiiol, 2011,58(24): e44-122.
  • 7Anderson JL, Adams CD,Antman EM, et al.2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the mangement of patients with unstable angina/non-ST-eleva-tion myocardial infarction: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines [ J ].J Am Coll Cardiol, 2013 , 61 (23): el79 - 347.
  • 8James S, Akerblom A, Cannon CP, et al.Comparison of ticagrelor ,the first reversible oral P2Y ( 12 ) receptor antagonist, with clopidogrel in patients with acute coronary syndromes : Rationale ,design,and baseline characteristics of the PLATelet inhibition and patient Outcomes ( PLATO) trial [ J].Am Heart J,2009, 157(4) : 599 -605.
  • 9Andereon JL, Adams CD, Antman EM, et al.2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/ non-ST-eleva-tion myocardial infarction : a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[ J ].Circulation, 2011,123(18): e426 -579.
  • 10Abergel E, Nikolsky E.Ticagrelor : an investigational oral anti-platelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome [ J ].Vase Health Risk Man-ag, 2010,6: 963 -977.

共引文献307

同被引文献28

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部